Delta-Fly Pharma, Inc.
4598.T · JPX
3/31/2025 | 3/31/2024 | 3/31/2023 | 3/31/2022 | |
|---|---|---|---|---|
| Market Cap | ¥5,060,099 | ¥4,328,961 | ¥3,411,092 | ¥3,260,837 |
| - Cash | ¥338,829 | ¥1,417,062 | ¥844,341 | ¥1,268,492 |
| + Debt | ¥0 | ¥0 | ¥0 | ¥0 |
| Enterprise Value | ¥4,721,270 | ¥2,911,899 | ¥2,566,751 | ¥1,992,345 |
| Revenue | ¥0 | ¥0 | ¥0 | ¥300,000 |
| % Growth | – | – | -100% | – |
| Gross Profit | -¥1,588 | -¥1,512 | -¥1,632 | ¥300,000 |
| % Margin | – | – | – | 100% |
| EBITDA | -¥1,717,074 | -¥1,402,000 | -¥1,324,126 | -¥960,000 |
| % Margin | – | – | – | -320% |
| Net Income | -¥1,721,164 | -¥1,429,393 | -¥1,328,788 | -¥967,302 |
| % Margin | – | – | – | -322.4% |
| EPS Diluted | -195.58 | -198.78 | -234.51 | -178.58 |
| % Growth | 1.6% | 15.2% | -31.3% | – |
| Operating Cash Flow | -¥1,834,577 | -¥1,279,615 | -¥1,303,049 | -¥940,399 |
| Capital Expenditures | -¥116 | -¥1,132 | -¥321 | ¥0 |
| Free Cash Flow | -¥1,834,693 | -¥1,280,747 | -¥1,303,370 | -¥940,399 |